Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 6/20 | 0.75 |
| ▸ | CNR1 | P21554 | 3/20 | 0.75 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.70 |
| ▸ | ESR1 | P03372 | 10/20 | 0.68 |
| ▸ | ESR2 | Q92731 | 10/20 | 0.68 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.61 |
| ▸ | NAPEPLD | Q6IQ20 | 1/20 | 0.61 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11550720 | 0.96 | CNR1 (0.67) | CNR2CNR1PAX8ESR1ESR2 | |
| SCHEMBL8733651 | 0.93 | CNR2 (0.66) | CNR2CNR1PAX8ESR1ESR2 | |
| SCHEMBL11547037 | 0.93 | CNR1 (0.62) | CNR2CNR1PAX8ESR1ESR2 | |
| SCHEMBL11545740 | 0.92 | ESR1 (0.67) | CNR2CNR1PAX8ESR1ESR2 | |
| SCHEMBL4651840 | 0.92 | ESR1 (0.67) | CNR2CNR1PAX8ESR1ESR2 | |
| SCHEMBL11555855 | 0.91 | ESR1 (0.68) | CNR2CNR1PAX8ESR1ESR2 | |
| SCHEMBL4650716 | 0.90 | CNR2 (0.72) | CNR2CNR1PAX8ESR1ESR2 | |
| SCHEMBL11550741 | 0.90 | CNR2 (0.72) | CNR2CNR1PAX8ESR1ESR2 | |
| SCHEMBL11548759 | 0.89 | ESR1 (0.66) | CNR2CNR1PAX8ESR1ESR2 | |
| SCHEMBL4651853 | 0.89 | CNR2 (0.71) | CNR2CNR1PAX8ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0895781-A2 | Use of benzofurans, benzothiophenes or indoles for the manufacture of a medicament for the treatment of conditions associated with an excess of tachykinins | ELI LILLY AND COMPANY (US) | 1999-02-10 | — | — | EP | claimed |
| EP-0735821-A4 | METHODS FOR THE TREATMENT OR PREVENTION OF CONDITIONS ASSOCIATED WITH AMYLOIDOGENIC REPTIDES | LILLY CO ELI (US) | 1998-04-01 | — | — | EP | claimed |
| US-5663192-A | PSYCHOLOGICAL DISORDERS USING INDOLE, BENZOTHIOPHENE OR BENZOFURANS WITH AMINO AND ALKOXYBENZOYL GROUPS | ELI LILLY AND COMPANY (US) | 1997-09-02 | — | — | US | claimed |
| EP-0736007-A4 | NON-PEPTIDE TACHYKININ RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 1997-03-19 | — | — | EP | claimed |
| EP-0736007-A1 | NON-PEPTIDE TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1996-10-09 | — | — | EP | claimed |
| EP-0735821-A1 | METHODS FOR THE TREATMENT OR PREVENTION OF CONDITIONS ASSOCIATED WITH AMYLOIDOGENIC REPTIDES | ELI LILLY AND COMPANY (US) | 1996-10-09 | — | — | EP | claimed |
| EP-0716854-A2 | Compositions for inhibiting neuropeptide y receptors | ELI LILLY AND COMPANY (US) | 1996-06-19 | — | — | EP | claimed |
| WO-1996012488-A1 | BICYCLIC BRADYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1996-05-02 | — | — | WO | claimed |
| EP-0709090-A2 | Compositions for treating resistant tumors | ELI LILLY AND COMPANY (US) | 1996-05-01 | — | — | EP | claimed |
| WO-1996011677-A1 | METHODS FOR TREATING RESISTANT TUMORS | ELI LILLY AND COMPANY (US) | 1996-04-25 | — | — | WO | claimed |
| EP-0707852-A2 | Bicyclic bradykinin receptor antagonists | ELI LILLY AND COMPANY (US) | 1996-04-24 | — | — | EP | claimed |
| WO-1995017095-A1 | METHODS FOR THE TREATMENT OR PREVENTION OF CONDITIONS ASSOCIATED WITH AMYLOIDOGENIC REPTIDES | ELI LILLY AND COMPANY (US) | 1995-06-29 | — | — | WO | claimed |
| WO-1995017382-A1 | NON-PEPTIDE TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1995-06-29 | — | — | WO | claimed |
| EP-1093803-B1 | Cosmetic composition comprising an antagonist of the neuropeptide Y receptor | SANOFI AVENTIS (FR) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007077333-A2 | USE OF A NEUROPEPTIDE Y ANTAGONIST FOR DAMAGED OR SENSITIVE LIPS | L'OREAL (FR) | 2007-07-12 | — | — | WO | disclosed |
| EP-0838217-B1 | Cosmetic composition containing neuropeptide Y receptor antagonist | SANOFI SYNTHELABO (FR) | 2003-01-15 | — | — | EP | disclosed |
| EP-1093803-A2 | Cosmetic composition comprising antagonist of the neuropeptide Y receptor | SANOFI-SYNTHELABO (FR) | 2001-04-25 | — | — | EP | disclosed |
| US-6114336-A | Cosmetic composition containing a neuropeptide Y receptor antagonist | SANOFI (FR) | 2000-09-05 | — | — | US | disclosed |
| EP-0838217-A2 | Cosmetic composition containing neuropeptide Y receptor antagonist | SANOFI (FR) | 1998-04-29 | — | — | EP | disclosed |
| US-4133814-A | ANTITUMOR AGENTS | ELI LILLY AND COMPANY (US) | 1979-01-09 | — | — | US | disclosed |